Written Question · S3W-38009 · Session 3
Whether it has considered the establishment of (a) a body or (b) specific methods at the Scottish Medicines Consortium to evaluate treatmen…
The question
To ask the Scottish Executive whether it has considered the establishment of (a) a body or (b) specific methods at the Scottish Medicines Consortium to evaluate treatments for rare diseases.
The answer
There are longstanding commissioning arrangements to ensure patients are able to benefit from specialised services for the treatment of rare and ultra-rare conditions. Access to this national resource is managed by the National Services Division (NSD) of NHS National Services Scotland, which commission relevant treatment within NHSScotland or from highly specialised services across the UK or further afield in Europe, as and when it is required.
The European Council published a recommendation on rare diseases in 2009 that proposes a national plan for rare diseases. The Scottish Government fully supports this recommendation and is working with officials from across the UK to explore the extent to which the UK meets the requirements of the recommendation and to agree areas of possible collaboration and progress in the future.
In relation to the evaluation of medicines, Scotland has robust, equitable and transparent arrangements for the introduction of newly licensed clinically and cost-effective medicines to treat all conditions, including rare diseases. In appraising orphan medicines to treat rare diseases, the Scottish Medicines Consortium may, in addition to the standard assessment of clinical and cost-effectiveness, apply modifiers which consider other additional factors. Subject to meeting certain criteria, this can facilitate acceptance of a medicine notwithstanding the economic evidence provided. Full details of the Scottish Medicines Consortium policies can be found on the SMC website:
http://www.scottishmedicines.org.uk/smc/3863.21.24.html.
NHS boards also have arrangements that provide an opportunity at local level for clinically led consideration of medicines for individual patients in certain circumstances.
The European Council published a recommendation on rare diseases in 2009 that proposes a national plan for rare diseases. The Scottish Government fully supports this recommendation and is working with officials from across the UK to explore the extent to which the UK meets the requirements of the recommendation and to agree areas of possible collaboration and progress in the future.
In relation to the evaluation of medicines, Scotland has robust, equitable and transparent arrangements for the introduction of newly licensed clinically and cost-effective medicines to treat all conditions, including rare diseases. In appraising orphan medicines to treat rare diseases, the Scottish Medicines Consortium may, in addition to the standard assessment of clinical and cost-effectiveness, apply modifiers which consider other additional factors. Subject to meeting certain criteria, this can facilitate acceptance of a medicine notwithstanding the economic evidence provided. Full details of the Scottish Medicines Consortium policies can be found on the SMC website:
http://www.scottishmedicines.org.uk/smc/3863.21.24.html.
NHS boards also have arrangements that provide an opportunity at local level for clinically led consideration of medicines for individual patients in certain circumstances.
In the Official Report
No contribution in the Official Report cites S3W-38009 by reference.